A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
22
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.

Conditions

Interventions

Sponsor

Amgen